Drug Trial Radar · NCT04444440
Antibiotic Prophylaxis for Bladder Botox
Last checked: Nov 20, 2026Latest source record: Sep 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
202
Planned (sponsor's estimate)
Start
Jun 28, 2021
Primary completion
Jun 30, 2028
Study completion Jun 30, 2028
Sponsor
- Lead sponsor
- University of AlbertaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Women and Children's Health Research Institute, Canada
- First posted
- Jun 23, 2020
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Injection of Botox into the bladder is a common treatment for overactive bladder. Postoperative bladder infection is one of the more frequently reported complications of this procedure. Prophylactic antibiotics given at the time of bladder Botox for the reduction of postoperative bladder infection have not been well studied. The main goal of our study is to determine if prophylactic antibiotics at the time of bladder Botox injection for the treatment of overactive bladder in women reduces postoperative bladder infection. The investigators are proposing a study which will randomize participants into two groups - one receiving Ciprofloxacin and the other receiving placebo pills for three days following the procedure. The primary outcome evaluated will be the difference in postoperative bladder infection between the two groups. The investigators will also investigate differences in reported side effects between the two groups possibly related to antibiotic use. Follow-up will be over six weeks following the procedure.
Conditions
- Idiopathic Overactive Bladder
- Postoperative Urinary Tract Infection
Interventions
CiprofloxacinDrug
Fluoroquinolone antibiotic.
Placebo PillOther
Placebo Pill
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rate of Postoperative Urinary Tract InfectionTime frame: 2 weeks following the procedure
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Urogynecology Clinic - Royal Alexandra Hospital
Edmonton, Alberta, Canada · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.